Hypercalcemia News and Research

RSS

Hypercalcemia or increased blood level of calcium is calcium found in a concentration that is higher than the usual range of 8.5 to 10.2 mg/dL. However, this normal value may vary slightly between different laboratories due to differences in protocols.

Surgery more effective than drug therapy in patients with tertiary hyperparathyroidism

A study led by researchers from the Nephrology group at Bellvitge Biomedical Research Institute (IDIBELL) and the University Hospital of Bellvitge (HUB), compared the results of surgery with drug therapy in patients with tertiary hyperparathyroidism, ie after a kidney transplant.

17 Dec 2015

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older.

19 Oct 2015

Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

3 Sep 2015

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire plc today announced that Natpara (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism on January 23, 2015.

1 Apr 2015

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.

5 Nov 2014

Calcium, vitamin D supplements may send blood levels too high for some women

Calcium and vitamin D are commonly recommended for older women, but the usual supplements may send calcium excretion and blood levels too high for some women, shows a new study published online today in Menopause, the journal of The North American Menopause Society.

18 Jun 2014

Drugs used to treat osteoporosis appear to prevent cell membrane repair

A class of drugs widely used to treat osteoporosis appears to impede a cell's ability to repair a protective outer membrane that helps determine what enters and exits, researchers report.

15 Apr 2014

Hope in sight for sufferers of chronic renal disease

Miss M. spends around 15 hours a week in hospital. Her renal functions are limited, and her kidneys are no longer able to filter toxins from her blood. She is a dialysis patient, forced to rely on this artificial blood purification treatment that, although essential, greatly impairs her quality of life. She has to make three trips a week to the dialysis clinic and going away for longer than a few days is almost out of the question. And Miss M. is no exception: In Germany alone, over six million people suffer from some form of chronic renal disease.

17 Jan 2014

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

OPKO reports more than 50% enrollment in phase 3 trial of Rayaldy for treatment of secondary hyperparathyroidism

OPKO Health, Inc., has surpassed 50% enrollment in the first phase 3 trial of RayaldyTM to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

24 May 2013

Calcipotriol drug offers a potential treatment option for fibrotic diseases

Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).

26 Apr 2013

Consortium database model compares favorably for RCC prognosis

The International Metastatic Renal-Cell Carcinoma Database has been externally validated and is now ready for application, researchers report.

20 Feb 2013

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

21 Sep 2012

Mushroom compound lengthens lives of dogs with cancer, has human potential

Dogs with splenic hemangiosarcoma had significantly delayed metastatic progression and lived longer than any previously recorded time after treatment with an extract of the mushroom Coriolus versicolor, report US investigators.

19 Sep 2012

Safe vitamin D treatment without raising calcium levels

Patients with a gland disorder that causes excessive calcium in their blood who also have vitamin D deficiency can safely receive vitamin D treatment without it raising their calcium levels, a new study has determined. The results with one-year follow-up will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

Vitamin D and calcium supplements could increase risk of kidney stones

Calcium and vitamin D supplements are associated with high calcium levels in the blood and urine, which could increase the risk of kidney stones, a new study finds. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

NexGen receives U.S. patent allowance for novel pathogenesis based seizure treatment

NexGen Biomedical, Inc.'s Founder has received a Notice of Allowance from the US Patent Office for a novel treatment method for seizures.

2 Mar 2012

Paricalcitol does not improve clinical outcomes for patients with CKD

Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the February 15 issue of JAMA.

15 Feb 2012

New discovery paves way for genetic screening test

Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors.

27 Jan 2012